|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 44.26 Million
|
|
CAGR (2025-2030)
|
3.51%
|
|
Fastest Growing Segment
|
Inactivated Influenza Vaccine
|
|
Largest Market
|
Northern & Central
|
|
Market Size (2030)
|
USD 53.81 Million
|
Market Overview
Saudi
Arabia Influenza Vaccine Market was valued at USD 44.26 Million in 2024 and is
expected to reach USD 53.81 Million by 2030 with a CAGR of 3.51% during the
forecast period.
The vaccine available in Saudi Arabia is a trivalent
influenza vaccine (TIV), which contains inactivated antigens from two subtypes
of influenza virus type A and one subtype of influenza virus type B. Upon
administration, the vaccine prompts the immune system to produce antibodies
against the influenza virus, helping to protect the individual from infection
if exposed to the virus. Saudi Arabia’s government plays a pivotal role in
promoting influenza vaccination programs through national health campaigns,
particularly in high-risk groups such as the elderly, pregnant women, and
individuals with chronic diseases. The Ministry of Health (MOH) has continuously
expanded its immunization initiatives, offering free vaccines through
healthcare facilities, mobile vaccination units, and awareness programs. These
efforts aim to reduce the burden of seasonal flu on the population,
particularly during peak flu seasons.
There
is a growing public awareness of the importance of preventive healthcare in
Saudi Arabia, especially after the COVID-19 pandemic. As people become more
health-conscious, they are increasingly opting for vaccinations, including
those for influenza, as a proactive measure to protect themselves from seasonal
illness. This cultural shift towards preventive medicine is driving the market
for influenza vaccines, as more individuals seek immunization to avoid the
seasonal flu's adverse health impacts.
Despite
growing awareness, vaccine hesitancy remains a challenge in certain segments of
the population. Misinformation regarding vaccine safety and efficacy,
compounded by reluctance from some individuals or communities to receive
vaccinations, poses an obstacle to achieving higher immunization rates.
Combating misinformation through public education and engagement remains
essential to overcoming this challenge and ensuring widespread vaccine uptake.
Key Report Takeaways
- Inactivated influenza vaccines are the fastest growing vaccine type in 2024, supported by a strong safety profile and suitability for elderly people, pregnant women, and immunocompromised patients.
- These vaccines do not contain live virus, lowering infection risk, while offering reliable seasonal flu protection during recurring outbreaks.
- Hospitals lead by distribution channel, as they serve as primary vaccination centers and support preventive healthcare programs across the country.
- Northern and Central regions, especially Riyadh, dominate due to high pilgrim inflow for Hajj and Umrah and strong private sector participation, with key players including GlaxoSmithKline plc, Abbott S.A., AstraZeneca PLC, Merck Limited, and Johnson and Johnson Medical Saudi Arabia Limited.
Key Market Drivers
Growth Prevalence of Influenza
The
growing prevalence of influenza is a significant driver of the Saudi Arabia
influenza vaccine market. As the incidence of seasonal flu rises globally,
including in Saudi Arabia, there is an increasing focus on preventive
healthcare measures, with vaccination being one of the most effective ways to
combat the spread of the virus. As of 2023, Saudi Arabia holds the 82nd
position globally for its seasonal influenza mortality rate, with 30.9 deaths
per 100,000 people. A meta-analysis of 62,431 individuals, drawn from 18
studies on Hajj pilgrims, reported an overall prevalence rate of 5.9% for
influenza type A and 3.6% for influenza type B. The Kingdom’s healthcare
system is responding to this challenge by prioritizing flu vaccination
programs, leading to a surge in demand for influenza vaccines.
The
Saudi government, in line with its broader public health objectives, has been
promoting vaccination campaigns to safeguard public health, particularly in
vulnerable groups such as the elderly, children, and individuals with chronic
health conditions. The King Khaled Eye Specialist Hospital (KKESH) in
Riyadh, Saudi Arabia, is a leading tertiary eye care institution. The hospital
provides complimentary influenza vaccines to its staff and their dependents
ahead of the flu season. Vaccination records for employees and their dependents
are electronically maintained for efficient tracking and management. These
efforts are part of the country’s commitment to strengthening its healthcare
infrastructure and improving disease prevention strategies. With the growing
understanding of the importance of vaccination in controlling influenza
outbreaks, the demand for flu vaccines is expected to continue increasing,
further propelling market growth.
Additionally,
the rise in healthcare awareness and the increased availability of vaccines
across various medical facilities, including hospitals, clinics, and
pharmacies, is contributing to the growing uptake of influenza vaccines. The
expanding access to flu shots, particularly during peak influenza seasons, is
enhancing public confidence in vaccination as a critical tool in disease
prevention. As the prevalence of influenza continues to grow, the Saudi Arabia
influenza vaccine market is positioned for sustained growth, driven by both
governmental initiatives and increasing public demand for effective preventive
healthcare solutions.
Surge in Technological Advancements
The
surge in technological advancements is a key driver of the growth in Saudi
Arabia’s influenza vaccine market. Continuous innovations in vaccine
development and production technologies are significantly enhancing the
effectiveness, accessibility, and speed at which vaccines are produced, thereby
increasing their adoption across the Kingdom. These advancements are improving
both the safety and efficiency of influenza vaccines, making them crucial tools
in the ongoing efforts to combat seasonal influenza outbreaks and potential
pandemics.
One
of the most notable technological advancements in the influenza vaccine market
is the development of more sophisticated vaccine production methods, such as
cell-based and recombinant DNA technologies. These innovations have led to the
production of vaccines that are not only more effective but also faster to
manufacture, addressing the ever-changing strains of the influenza virus.
Cell-based production systems, for example, allow for quicker production times
compared to traditional egg-based methods, enabling vaccines to be produced and
distributed more rapidly, especially during flu seasons.
Additionally,
advancements in adjuvant technology, which enhances the body’s immune response
to the vaccine, have improved vaccine efficacy, particularly in older adults
and individuals with weakened immune systems. These adjuvants boost the immune
response, making the vaccine more effective in protecting against flu strains
that may vary from season to season.
Download Free Sample Report
Key Market Challenges
Vaccine Storage and Shelf Life
Ensuring
that influenza vaccines remain at optimal temperatures throughout their storage
and distribution is critical to their effectiveness. Cold chain logistics
involve specialized equipment and infrastructure, such as refrigeration units
and temperature monitoring systems, which must be available at every step, from
production and transport to final administration. In Saudi Arabia, the high
temperatures, especially during summer, put additional strain on maintaining
these cold chain conditions, increasing the risk of temperature excursions that
could degrade the vaccine.
These
challenges are especially prevalent in rural areas or regions with limited
healthcare infrastructure, where access to advanced refrigeration facilities
may be limited. Any disruption in the cold chain can lead to reduced vaccine
potency, rendering doses ineffective and leading to vaccine wastage. The cost
of managing these logistical hurdles can also increase the overall expenses
associated with vaccine distribution.
Another
challenge in the influenza vaccine market is the limited shelf life of
vaccines. Influenza vaccines are typically developed annually based on the
predicted strains for the upcoming flu season, meaning they have a short window
of use. Healthcare providers and distributors must manage inventory carefully to
avoid vaccine expiration, which can lead to financial losses and decreased
vaccine availability.
Key Market Trends
Rising Demand for Pediatric
Vaccines
The
rising demand for pediatric vaccines is an important trend shaping the growth
of the Saudi Arabia influenza vaccine market. As part of the Ministry of
Health's (MOH) ongoing initiative to promote influenza vaccination, a home
vaccination service is now accessible via the Careem application. This service
is available in Riyadh, Dammam, Makkah Al-Mukarramah, Madinah, and Jeddah. With
an increasing focus on protecting vulnerable populations, including children,
from seasonal influenza, there has been a significant push towards promoting
pediatric flu vaccinations. This trend aligns with the country’s broader public
health objectives of reducing the burden of influenza-related illnesses among
children, who are more susceptible to complications from the virus.
The
growing awareness among parents and healthcare providers about the importance
of early vaccination for children has led to an increase in demand for
pediatric flu vaccines. Government initiatives, including awareness campaigns
and vaccination drives, are playing a pivotal role in encouraging parents to
immunize their children against influenza. Schools, pediatric clinics, and
healthcare centers are increasingly adopting these vaccines as part of routine
immunization programs, ensuring wider coverage and protection for the younger
population.
Moreover,
the Saudi Ministry of Health’s ongoing efforts to expand access to vaccines,
coupled with its emphasis on preventive healthcare, are further boosting the
demand for pediatric flu vaccines. As the Kingdom continues to enhance its
healthcare services and prioritize pediatric health, the rising demand for these
vaccines is expected to be a key driver of growth in the influenza vaccine
market. This trend reflects a growing commitment to safeguarding children’s
health and reducing the incidence of flu-related complications among the
younger population in Saudi Arabia.
Segmental Insights
Vaccine Type Insights
Inactivated influenza vaccines are gaining traction in Saudi Arabia because they use the dead version of the germ and are widely considered suitable for broad population coverage, including groups prioritized in seasonal campaigns. Saudi health guidance also emphasizes protecting higher-risk groups such as people with chronic diseases, adults over age 50, children ages six months to five years, pregnant women and health care workers, which aligns with the broad-use profile of inactivated influenza vaccines. For instance, the Ministry of Health said 96% of patients admitted to intensive care units with seasonal influenza had not received the vaccine, reinforcing the focus on prevention and uptake in vulnerable groups.
Distribution Channel Insights
Hospitals are central to influenza vaccination delivery in Saudi Arabia because they serve high-risk patients and operate within a large, expanding care network that supports seasonal surges. Government health workforce statistics show the Kingdom had 516 hospitals in 2024, along with 23.4 hospital beds per 10,000 population and 129,772 physicians, supporting capacity to administer preventive services at scale during flu season. For instance, the Ministry of Health said the seasonal influenza vaccine can be booked through the Sehhaty application, which helps direct eligible patients into clinical settings and organized vaccination workflows.
Download Free Sample Report
Regional Insights
Based
on Region, Northern & Central have emerged as the dominating region in the Saudi
Arabia Influenza Vaccine Market in 2024. Riyadh and other Central cities serve
as major hubs for pilgrims traveling to Mecca and Medina. With millions of
pilgrims visiting Saudi Arabia each year, the Saudi government encourages
influenza vaccination as part of the health protocols for those undertaking
Hajj and Umrah pilgrimages. As a result, the Central region sees a surge in
demand for flu vaccines, not only from local residents but also from travelers,
further boosting its market share.
The
private healthcare sector plays a significant role in the Northern and Central
regions, particularly in Riyadh. Private hospitals, clinics, and pharmacies
offer influenza vaccinations as part of corporate wellness programs and
individual healthcare services. The engagement of the private sector in
vaccination efforts, alongside government initiatives, contributes to the
dominance of these regions in the overall market.
Recent Development
- In November 2025, a NUPCO tender listing indicated procurement activity for “Influenza Virus Vaccine High Dose Trivalent Injection in Pre-Filled Syringe,” reflecting continued tendering for newer high-dose influenza vaccine formats.
- In September 2025, Saudi Arabia’s Ministry of Health announced seasonal influenza vaccination appointments could be booked via the Sehhaty app, increasing access points for the annual flu campaign.
- In October 2025, CSL Seqirus stated the collaboration would include establishing pre-pandemic vaccine stockpiles for high-risk populations and an Advance Purchase Agreement for pandemic vaccines for the broader population.
- In
2023, the Saudi Ministry of Health initiated various seasonal influenza
vaccination awareness campaigns over the years, targeting high-risk groups such
as healthcare workers, pregnant women, individuals with chronic conditions,
children, and the elderly. These initiatives have successfully resulted in
higher vaccination rates among healthcare workers.
- In
September 2024, Saudi Arabia's Ministry of Health launched a groundbreaking
initiative, becoming the first country worldwide to provide free home services
for seasonal influenza vaccinations. This service is accessible via the Sanar
application, enabling users to schedule vaccination visits at their preferred
location and time. The initiative is designed to improve vaccine accessibility,
with a particular focus on vulnerable groups, including children, the elderly,
individuals with chronic conditions, pregnant women, and healthcare workers.
Key Market Players
|
By Vaccine Type
|
By Distribution Channel
|
By Region
|
- Inactivated Influenza Vaccine
- Live Attenuated Influenza Vaccine
|
- Hospital
- Retail Pharmacies
- Government Suppliers
- Others
|
- Eastern
- Western
- Northern & Central
- Southern
|
Report Scope
In this report, the Saudi Arabia Influenza Vaccine
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Saudi Arabia Influenza Vaccine Market, By Vaccine Type:
o Inactivated Influenza Vaccine
o Live Attenuated Influenza Vaccine
- Saudi Arabia Influenza Vaccine Market, By Distribution Channel:
o Hospital
o Retail Pharmacies
o Government Suppliers
o Others
- Saudi Arabia Influenza Vaccine Market, By
Region:
o Eastern
o Western
o Northern & Central
o Southern
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Saudi
Arabia Influenza Vaccine Market.
Available Customizations:
Saudi Arabia Influenza Vaccine Market report with
the given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Saudi Arabia Influenza
Vaccine Market is an upcoming report to be released soon. If you wish an early
delivery of this report or want to confirm the date of release, please contact
us at
[email protected]